Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

SANOFI INDIA LTD.

NSE : SANOFIBSE : 500674ISIN CODE : INE058A01010Industry : Pharmaceuticals & DrugsHouse : Sanofi India - MNC

BSE5955.6566 (+1.12 %)

PREV CLOSE ( ) 5889.65

OPEN PRICE ( ) 5969.60

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 760

TODAY'S LOW / HIGH ( )5919.05 6000.00

52 WK LOW / HIGH ( )4145.9 7593.6

NSE5972.0087 (+1.48 %)

PREV CLOSE( ) 5885.00

OPEN PRICE ( ) 5899.50

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 9217

TODAY'S LOW / HIGH( ) 5899.50 6000.50

52 WK LOW / HIGH ( )4902 7600

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 02-05 1956

Management Info

Aditya Narayan - Chairman - Managing Director

Registered Office

Address Sanofi House, C T S No. 117- B,L & T Business Park,Saki Vihar Road, Powai,
Mumbai,
Maharashtra-400072

Phone 022-2803 2000

Email igrc.sil@sanofi.com

Website www.sanofiindialtd.com

Registrars Details

MUFG Intime India Pvt Ltd.

C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai

Listing : BSE, NSE

NEWS

16Jul Appointment of Director
Inter-alia considered and approved the following matters: 1. With refer..

16Jul Resignation of Director
Inter-alia considered and approved the following matters: 1. With refer..

24May Sanofi India informs about change in m
Sanofi India has informed that upon the recommendation of the Nomination..

25Apr Sanofi India informs about disclosure
In compliance with Regulation 30 of the SEBI (LODR) Regulations, Sanofi..

24Apr Sanofi India informs about disclosure
In compliance with Regulation 30 of the SEBI (LODR) Regulations, Sanofi..

Financials

Rs. in Millions

	QTR Mar 25	ANNUAL 24
Net Profit	1195	4135
Gross Profit	1653	4314
Operating Profit	1752	5073
Net Sales	5359	20132

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Astrazeneca Pharma I (BSE) 9386.25 (2.44%)	M.Cap ( in Cr)23465.63
Neuland Laboratories (BSE) 14496.35 (0.67%)	M.Cap ( in Cr)18598.66
Hester Biosciences (BSE) 1946.45 (4.57%)	M.Cap ( in Cr)1655.82
Concord Biotech (BSE) 1921.55 (4.55%)	M.Cap ( in Cr)20102.53
Torrent Pharma (BSE) 3504.35 (1.22%)	M.Cap ( in Cr)118603.13

Shareholding Pattern

	PROMOTERS	60.4%
	FI/BANKS/INSURANCE	11.75%
	MUTUAL FUNDS/UTI	11.26%
	NON-INSTITUTION	11.01%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
Baroda BNP Paribas ...	1.98
Nippon India Pharma...	1.71
PGIM India Healthca...	1.65
Aditya Birla SL Pha...	1.46
Baroda BNP Paribas ...	1.21
Baroda BNP Paribas ...	1.18
SBI Midcap Fund-Reg(G)	1.15

Risk Disclosures on Derivatives

Smart Quotes

SANOFI INDIA LTD.